title: Leveraging the species barrier to advance cancer therapy.
abstract: The discovery of new therapeutic targets and the personalization of treatments are two active areas of cancer research. New studies suggest that a 'co-clinical' approach may expedite both therapeutic target validation and risk stratification in patients with advanced prostate cancer.
authors.forename: Song
authors.initials: S
authors.lastname: Zhao
authors.forename: Peter S
authors.initials: PS
authors.lastname: Nelson
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000728:Androgens / Q000378:metabolism*; D000818:Animals; D016922:Cellular Senescence / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000502:physiology*; D005260:Female; D016147:Genes, Tumor Suppressor; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D055758:SOX9 Transcription Factor / Q000235:genetics*; D035703:Therapies, Investigational; D014157:Transcription Factors / Q000502:physiology*
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D004268:DNA-Binding Proteins; D055758:SOX9 Transcription Factor; C527932:SOX9 protein, human; D014157:Transcription Factors; C485514:ZBTB7A protein, human